Tempus and Personalis Launch Commercialization of Advanced Cancer MRD Testing with NeXT Personal Dx Assay
FREMONT, Calif. ’ Personalis, Inc. (Nasdaq: PSNL), a pioneering force in advanced genomics for precision oncology, has announced a significant collaborative venture with Tempus, a prominent technology company advancing the connection between molecular data and real-world evidence for better healthcare outcomes. This partnership heralds the commencement of concerted commercialization efforts surrounding Personalis’ revolutionary liquid biopsy assay, NeXT Personal, which is designed to detect minimal residual disease (MRD) and potential recurrence of cancer in patients.
NeXT Personal is an ultra-sensitive, whole genome-based liquid biopsy assay that stands at the forefront of MRD detection technology. As part of this collaboration, members of the Tempus commercial team are now equipped to engage in detailed discussions with oncologists and healthcare providers regarding the diagnostic capabilities of the NeXT Personal Dx test, particularly for breast and lung cancer patients.
The fusion of Personalis’ cutting-edge genomic advancements with Tempus’ robust commercial framework marks a significant step toward broadening access to this vital diagnostic tool. By leveraging Tempus’ extensive network and expertise in integrating molecular data with clinical practice, the partnership aims to enhance the early detection and monitoring of cancer recurrence, thereby potentially improving patient outcomes and paving the way forward in the fight against cancer.
In summary, the combination of Personalis’ NeXT Personal assay with Tempus’ commercial prowess sets a new standard for MRD testing, offering a promising avenue for precision oncology. The strategic alliance underscores a shared commitment to utilizing genomic innovations to transform cancer care, ensuring that patients receive the most accurate, timely, and effective treatment possible.
Comments